Xingui Liu

Assistant Professor

University of Florida

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Xingui Liu is an Assistant Professor at the University of Florida, USA. His research focuses on the development of proteolysis-targeting chimeras (PROTACs) for therapeutic applications in biology and medicine, particularly in hematologic malignancies and cancer treatment. Recent publications include studies on novel PROTAC degraders that enhance selectivity and reduce side effects in cancer therapies.

Articles (10)

Year:

2023

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (6)

Rui Moreira

Full Professor

Faculty of Pharmacy, University of Lisbon

PORTUGAL

View details

Khan Sajid

Assistant Professor/Research

University of Texas Health Science Center at San Antonio

UNITED STATES

View details

Esther Sammler

UNITED KINGDOM

View details

Dongwen Lv

Assistant Professor

UT Health San Antonio

UNITED STATES

View details

Dongwen Lv

University of Texas Health Science Center at San Antonio

UNITED STATES

View details

Alessio Ciulli

Professor

University of Dundee

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Xingui Liu

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Proximity-Based Modalities for Biology and Medicine

Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood-Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2

Discovery of a Novel BCL-X<sub>L</sub>PROTAC Degrader with Enhanced BCL-2 Inhibition

PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity

Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity.

Assays and technologies for developing proteolysis targeting chimera degraders

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

Deuteration of the farnesyl terminal methyl groups of δ-tocotrienol and its effects on the metabolic stability and ability of inducing G-CSF production

Synthesis and Liver Microsomal Metabolic Stability Studies of a Fluorine‐Substituted δ‐Tocotrienol Derivative

Collaborators (6)

Rui Moreira

Khan Sajid

Esther Sammler

Dongwen Lv

Dongwen Lv

Alessio Ciulli

Make your next move.